Table 2 Number of participants in each AZD0530 treatment group experiencing an adverse event
Treatment group (AZD0539 dose; n = 6 per group) | |||||
|---|---|---|---|---|---|
Adverse event | Placebo | 50 mg | 100 mg | 125 mg | Total |
Any adverse event* | 3 | 4 | 5 | 4 | 16 |
Diarrhea | 2 | 0 | 1 | 2 | 5 |
Headache | 2 | 1 | 1 | 1 | 5 |
Fatigue | 1 | 0 | 0 | 2 | 3 |
Nausea | 2 | 0 | 0 | 1 | 3 |
Pneumonia, atypical/bronchitis | 0 | 0 | 0 | 1 | 1 |
Congestive heart failure | 0 | 0 | 0 | 1 | 1 |
Renal insufficiency, worsened | 0 | 0 | 0 | 1 | 1 |
Elevated serum creatinine | 0 | 0 | 0 | 1 | 1 |
Cough, worsened | 0 | 0 | 0 | 1 | 1 |
Postnasal drip | 0 | 0 | 0 | 1 | 1 |
Pulmonary hypertension | 0 | 0 | 0 | 1 | 1 |
Anorexia | 0 | 0 | 0 | 1 | 1 |
Tinnitus | 0 | 0 | 0 | 1 | 1 |
Myalgias | 0 | 0 | 0 | 1 | 1 |
Squamous cell carcinoma | 0 | 0 | 1 | 0 | 1 |
Basal cell carcinoma | 0 | 0 | 1 | 0 | 1 |
Wrist pain | 0 | 0 | 1 | 0 | 1 |
Noncardiac chest pain | 0 | 0 | 1 | 0 | 1 |
Upper respiratory infection | 0 | 1 | 0 | 0 | 1 |
Flu-like symptoms | 0 | 1 | 0 | 0 | 1 |
Lightheadedness | 0 | 1 | 0 | 0 | 1 |
Vomiting | 1 | 0 | 0 | 0 | 1 |